Why prices are set to rise
Cancer treatments using common platinum‑based drugs such as carboplatin, oxaliplatin, and cisplatin are likely to become more expensive in India, because the price of platinum—a key raw material—has nearly doubled over the past six months. Local drugmakers say the current government‑imposed ceiling prices have become “commercially unviable,” and are asking the National Pharmaceutical Pricing Authority (NPPA) for a 50% increase in the maximum retail price of these medicines.
What this means for patients
Platinum‑based chemotherapies form the backbone of first‑line treatment for several cancers, including head and neck, breast, gastrointestinal, and ovarian cancers, and are widely used because they are relatively affordable compared with newer immunotherapies or antibody‑drug conjugates. If the proposed hike is approved, monthly chemotherapy cycles that currently cost a few thousand rupees per vial could see steep increases, adding to the financial burden on patients already paying lakhs in total cancer‑care costs.
Industry’s argument vs public‑health risk
Drug manufacturers argue that the low ceiling prices, unchanged for years, leave them with little incentive to produce these essential agents reliably, creating a risk of supply shortages despite the rising platinum cost. At the same time, oncologists warn that any substantial price jump could reduce access for low‑ and middle‑income patients, especially in states where government‑funded schemes rely on these cheap platinum regimens as standard‑of‑care treatments. The NPPA’s response will now be closely watched, as it will decide whether affordability or manufacturer viability takes precedence in this critical class of medicines.
